SOX方案与FOLFOX4治疗进展期胃癌的临床疗效、毒副作用及生存时间比较研究

目的:探讨SOX方案与FOLFOX4治疗进展期胃癌的临床疗效、毒副作用及生存时间。方法:选取2013年10月到2014年10月期间唐山市人民医院收治的进展期胃癌患者90例作为研究对象,根据随机数字表法将其分为SOX组与FOLFOX4组,两组均为45例。SOX组患者给予奥沙利铂+替吉奥胶囊进行治疗,FOLFOX4组给予奥沙利铂+亚叶酸钙+氟尿嘧啶进行治疗。比较两组患者的疾病缓解率、疾病控制率、毒副反应、1年生存率、2年生存率和3年生存率。结果:两组患者的的疾病缓解率和疾病控制率经统计分析差异均无统计学意义(P0.05)。两组患者红细胞下降、血小板下降、腹泻、外周神经症状、手足综合征、肝功能异常发生率比较差异均无统计学意义(P0.05),FOLFOX4组I-II级白细胞下降、恶心呕吐的发生率高于SOX组(P0.05),两组III-IV级白细胞下降、恶心呕吐的发生率比较差异无统计学意义(P0.05)。两组患者的1年生存率、2年生存率、3年生存率经统计分析差异均无统计学意义(P0.05)。结论:SOX方案与FOLFOX4治疗进展期胃癌的临床疗效相近,且患者的生存时间无明显差异,但SOX方案的白细胞下降、恶心呕吐等毒副反应程度较轻。

Comparative Study of Clinical Efficacy of SOX and FOLFOX4 in Treatment of Advanced Gastric Cancer

ABSTRACT Objective: To investigate the clinical efficacy, toxic side effects and survival time of SOX and FOLFOX4 in the treatment of advanced gastric cancer. Methods: A total of 90 patients with advanced gastric cancer, who were treated in Tangshan City people''s Hospital from October 2013 to October 2014 were selected and randomly divided into SOX group(n=45) and FOLFOX4 group(n=45).The patients in SOX group were treated with oxaliplatin plus S1 capsule, and the patients in FOLFOX4 group were treated with oxaliplatin plus calcium folate plus fluorouracil. The disease remission rate,disease control rate,toxic side effects, 1 year of survival rate, 2 years of survival rate and 3 years of survival rate were compared between the two groups. Results: There was no statistical difference in the disease remission rate and disease control rate between the two groups by statistical analysis(P>0.05). There was no significant difference in the incidence of erythrocyte descen, thrombocytopenia,diarrhea,peripheral nerve symptoms, hand foot syndrome and liver dysfunction between the two groups (P>0.05). The incidence of I-II grade leucocyte descen and nausea and vomiting in FOLFOX4 group was higher than that in SOX group (P<0.05), and there was no significant difference in the incidence of III-IV grade leucocyte descen and nausea and vomiting between the two groups (P>0.05). There was no significant difference in 1 year of survival rate, 2 years of survival rate and 3 years of survival rate between the two groups by statistical analysis(P>0.05). Conclusion: The clinical efficacy of SOX regimen is similar to that of FOLFOX4 regimen in the treatment of advanced gastric cancer, and the survival time of patients is not significantly different.But the degree of toxic side effects such as leukocyte decline, nausea and vomiting is mild in the SOX regimen.